Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 88, Issue 5, 2014, Pages 1041-1047

  Chen, Shang Wen ^a,c,d,e   Lin, Li Ching ^b,d   Kuo, Yu Cheng ^c,f   Liang, Ji An ^c,e   Kuo, Chia Chun ^a   Chiou, Jeng Fong ^a,d  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCELLULAR CARCINOMA; INITIAL ASSESSMENT; METHODS AND MATERIALS; PARTIAL REMISSION; PORTAL VEIN THROMBOSIS; PROGRESSION FREE SURVIVAL; PROGRESSIVE DISEASE; TRANSARTERIAL CHEMOEMBOLIZATION;

RADIOTHERAPY;

TOXICITY;

SORAFENIB;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER OF THE LIVER ITALIAN PROGRAM SCORE; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SIZE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DUODENUM ULCER; FEMALE; HAND FOOT SYNDROME; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TOXICITY; MALE; MIDDLE AGED; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION INJURY; RADIOTHERAPY PLANNING SYSTEM; SCORING SYSTEM; STOMACH ULCER; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHEMORADIOTHERAPY; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROSIS; HAND-FOOT SYNDROME; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PORTAL VEIN; RADIATION DOSAGE; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84897907751     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.01.017     Document Type: Article

References (25)

1. A. Jemal, F. Bray, and M.M. Center et al. Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: An update Hepatology 35 2011 1020 1055
3. M.A. Hawkins, and L.A. Dawson Radiation therapy for hepatocellular carcinoma: From palliation to cure Cancer 106 2006 1653 1663
4. J.C. Cheng, V.P. Chuang, and S.H. Cheng et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma Int J Radiat Oncol Biol Phys 47 2000 435 442
5. K. Yamada, K. Izaki, and K. Sugimoto et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma Int J Radiat Oncol Biol Phys 57 2003 113 119
6. S. Wilhelm, and D.S. Chien BAY 43-9006: Preclinical data Curr Pharm Des 8 2002 2255 2257
7. J.M. Llovet, S. Ricci, and V. Mazzaferro et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
8. A.L. Cheng, Y.K. Kang, and Z. Chen et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo controlled trial Lancet Oncol 10 2009 25 34
9. Q. Li, Y. Hu, and M. Xi et al. Sorafenib modulates the radiosensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner BMC Cancer 12 2012 485
10. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
11. European Association for the Study of the Liver EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma J Hepatol 56 2012 908 943
12. L.A. Dawson Overview: Where does radiation therapy fit in the spectrum of liver cancer local-regional therapies? Semin Radiat Oncol 21 2011 241 246
13. S.X. Liang, X.D. Zhu, and Z.Y. Xu et al. Radiation-induced liver disease in three-dimensional conformal radiotherapy for primary liver carcinoma: The risk factor and hepatic radiation tolerance Int J Radiat Oncol Biol Phys 65 2006 426 434
14. National Cancer Institute. Common terminology criteria for adverse events version 4.0 (CTCAE). 2009. Available at http://evs.nci.nih.gov/ftp1/CTCAE/ CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf. Accessed May, 2009.
15. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
16. T.S. Lawrence, J.M. Robertson, and M.S. Anscher et al. Hepatic toxicity resulting from cancer treatment Int J Radiat Oncol Biol Phys 31 1995 1237 1248
17. J.C. Cheng, C.H. Chou, and M.L. Kuo et al. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NFkappaB signal transduction pathway Oncogene 25 2006 7009 7018
18. Y.L. Chung, J.J. Jian, and S.H. Cheng et al. Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: Implications for radiotherapy of hepatocellular carcinoma Clin Cancer Res 12 2006 2706 2715
19. J.P. Plastaras, S.H. Kim, and Y.Y. Liu et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation Cancer Res 67 2007 9443 9454
20. A.T. Wild, N. Gandhi, and S.T. Chettiar et al. Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma PLoS One 8 2013 e65726
21. L.A. Dawson, A. Brade, and C. Cho et al. Phase I study of sorafenib and stereotactic radiotherapy for advanced hepatocellular carcinoma Int J Radiat Oncol Biol Phys 84 2012 S10 S11
22. L. Llanos, P. Bellot, and P. Zapater et al. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib Am J Gastroenterol 104 2009 257 258
23. H.C. Park, J. Seong, and K.H. Han et al. Dose-response relationship in local radiotherapy for hepatocellular carcinoma Int J Radiat Oncol Biol Phys 54 2002 150 155
24. D.Y. Kim, W. Park, and D.H. Lim et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma Cancer 103 2005 2419 2426
25. T.H. Kim, D.Y. Kim, and J.W. Park et al. Thee-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable Am J Clin Oncol 29 2006 568 575